Efficacy of autologous platelet rich plasma on morphea: A comparative clinical and ultrasonographic follow up study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202301820107782

Enrollment

Registered

2023-01-13

Start date

2021-06-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin and Connective Tissue Diseases

Interventions

Platelet rich plasma

ultrasound assessment of contralateral healthy area

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with acute or chronic morphea

Exclusion criteria

Exclusion criteria: 1- Patients using anti-coagulation therapy, non-steroidal anti-inflammatory drugs, 2- patients having other connective tissue autoimmune diseases, chronic liver disease, blood diseases, critical thrombocytopenia or HIV and uncontrolled diabetes. 3- Patients who received topical or systemic treatment for morphea in the last month.

Design outcomes

Primary

Measure	Time frame
clinical cosmetic improvement using the Localized Scleroderma Assessment Tool (LoSCAT).	—

Secondary

Measure	Time frame
Ultrasonographic improvement using high frequency linear transducer machine	—

Countries

Egypt

Contacts

Public ContactMahmoud Makky

Assistant professor dermatology department

makkiderma@yahoo.com00201068753876

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026